Caribou Biosciences, Inc. Debt Securities, Available-for-sale, Current
Caribou Biosciences, Inc. (CRBU) had Debt Securities, Available-for-sale, Current of $86.12 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Current $86.12M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $105.57M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $126.98M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $136.12M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $86.12M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $105.57M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $126.98M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $136.12M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $158.75M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $179.05M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $193.24M 10-K · filed 2026-03-05 |
| 2024-09-30 | $196.21M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $223.78M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $244.59M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $277.67M 10-K · filed 2025-03-10 |
| 2023-09-30 | $234.43M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $193.04M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $175.79M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $189.32M 10-K · filed 2024-03-11 |
| 2022-09-30 | $211.28M 10-Q · filed 2022-11-08 |
| 2021-12-31 | $135.41M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |